Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) have received a consensus recommendation of “Moderate Buy” from the ten research firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $41.7778.

A number of equities research analysts have weighed in on the company. Barclays lifted their price objective on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. Truist Financial boosted their price target on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Monday, April 20th. UBS Group boosted their price target on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Finally, Wall Street Zen raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Saturday, June 6th.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, EVP Richard Daniell sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $35.40, for a total transaction of $1,062,000.00. Following the sale, the executive vice president owned 55,755 shares of the company’s stock, valued at $1,973,727. The trade was a 34.98% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Amir Weiss sold 10,679 shares of the business’s stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $36.00, for a total value of $384,444.00. Following the sale, the chief accounting officer directly owned 20,016 shares in the company, valued at $720,576. This trade represents a 34.79% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 465,931 shares of company stock worth $16,332,989. Corporate insiders own 0.54% of the company’s stock.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Institutional investors have recently modified their holdings of the company. Aster Capital Management DIFC Ltd purchased a new stake in Teva Pharmaceutical Industries in the 4th quarter valued at approximately $25,000. Cornerstone Planning Group LLC lifted its stake in Teva Pharmaceutical Industries by 547.1% in the 1st quarter. Cornerstone Planning Group LLC now owns 893 shares of the company’s stock valued at $27,000 after buying an additional 755 shares in the last quarter. Allworth Financial LP lifted its stake in Teva Pharmaceutical Industries by 53.8% in the 4th quarter. Allworth Financial LP now owns 941 shares of the company’s stock valued at $29,000 after buying an additional 329 shares in the last quarter. Grove Bank & Trust lifted its stake in Teva Pharmaceutical Industries by 300.0% in the 4th quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock valued at $31,000 after buying an additional 750 shares in the last quarter. Finally, EverSource Wealth Advisors LLC lifted its stake in Teva Pharmaceutical Industries by 51.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock valued at $32,000 after buying an additional 345 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA opened at $33.24 on Monday. Teva Pharmaceutical Industries has a twelve month low of $14.99 and a twelve month high of $37.35. The stock’s 50 day moving average is $33.73 and its two-hundred day moving average is $32.42. The firm has a market capitalization of $38.22 billion, a PE ratio of 24.99, a P/E/G ratio of 4.06 and a beta of 0.84. The company has a current ratio of 1.01, a quick ratio of 0.78 and a debt-to-equity ratio of 1.70.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $0.53 earnings per share for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%.The company had revenue of $3.98 billion for the quarter. Research analysts anticipate that Teva Pharmaceutical Industries will post 1.97 earnings per share for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.